USA flag logo/image

An Official Website of the United States Government

NEW INOTROPIC AGENTS FOR THE TREATMENT OF HEART FAILURE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60295
Program Year/Program:
2002 / STTR
Agency Tracking Number:
HL067498
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
RELIABLE BIOPHARMACEUTICAL CORPORATION
RELIABLE BIOPHARMACEUTICAL CORP. BOX 2517, 1945 WALTON RD ST. LOUIS, MO 63114
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: NEW INOTROPIC AGENTS FOR THE TREATMENT OF HEART FAILURE
Agency: HHS
Contract: 1R41HL067498-01A1
Award Amount: $134,076.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of the project is to develop new positive inotropes, represented by specifically modified AMP molecules. All of the currently available positive inotropic agents have significant adverse effects with digitalis being the only orally available positive inotrope. ATP causes a pronounced positive inotropic effect. Receptors for ATP, known as P2 purinergic receptor, has been shown to mediate its positive inotropic effect. However, agonists acting at this cardiac P2 receptor with enhanced efficacy, potency and selectivity, are lacking. Preliminary data suggest that certain specific modifications of the AMP molecule will confer positive inotropic activity and selectivity vs. the vascular P2 receptor. Adult rat ventricular myocytes and intact heart model have been developed to determine the affinity and efficacy of new agents at the myocyte P2 receptor and their effects on the various functional parameters in the intact heart. The overall objective of the study is to use these cardiac models to test these specifically modified AMP molecules at the cardiac P2 receptor. New chemical structures will be correlated with the affinity and the positive inotropic activity and cardiac vs. vascular P2 receptor selectivity. The effects of these compounds on the heart rate and blood pressure in conscious rats will also be determined. The studies may lead to potentially useful new positive inotropic agents for the treatment of heart failure.

Principal Investigator:

Bruce T. Liang

Business Contact:

Joseph Toce
3144297700
Small Business Information at Submission:

RELIABLE BIOPHARMACEUTICAL CORPORATION
RELIABLE BIOPHARMACEUTICAL CORP. BOX 2517, 1945 WALTON RD ST. LOUIS, MO 63114

EIN/Tax ID: 430959527
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF CONNECTICUT HEALTH CENTER
UNIVERSITY OF CONNECTICUT HEALTH CENTER
FARMINGTON, CT 06030
RI Type: Nonprofit college or university